Fig. 1: Therapeutic efficacy of fangchinoline in vitro and in vivo. | Cell Death & Disease

Fig. 1: Therapeutic efficacy of fangchinoline in vitro and in vivo.

From: Fangchinoline suppresses conjunctival melanoma by directly binding FUBP2 and inhibiting the homologous recombination pathway

Fig. 1: Therapeutic efficacy of fangchinoline in vitro and in vivo.

A Schematic of the phenotypic screening protocol from which fangchinoline was discovered to be a potent inhibitor of CM-AS16 cell proliferation. B Inhibition curve of fangchinoline against CM-AS16 cells based on the CCK-8 assay. The results are shown as the mean ± SD (n = 3). C Tumour volume of CM-AS16 tumour xenografts in NCG mice. Mice were treated with increasing doses of fangchinoline (0, 25, and 50 mg/kg/d) or MEK162 (50 mg/kg/d) for 22 days (n = 7). Notably, three mice under 25 mg/kg fangchinoline treatment died before killing. After 22 days, the mice were killed and the tumours were removed and analysed. D Body weight changes in control and drug-treated NCG mice. Data represent the mean ± SD, n = 7 per group. *P < 0.05, **P < 0.01, ****P < 0.0001, by two-way ANOVA.

Back to article page